Compare SOAR & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SOAR | MDCX |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 10.9M |
| IPO Year | 2021 | 2025 |
| Metric | SOAR | MDCX |
|---|---|---|
| Price | $0.31 | $0.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | ★ 43.7M | 2.6M |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 104.83 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.14 |
| 52 Week High | $4.36 | $2.78 |
| Indicator | SOAR | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 59.78 | 23.33 |
| Support Level | $0.14 | N/A |
| Resistance Level | $0.35 | $0.19 |
| Average True Range (ATR) | 0.04 | 0.01 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 44.40 | 9.41 |
Volato Group Inc is an aviation technology company that connects travelers to private, on-demand flight access and develops proprietary software platforms for enterprise and operational applications. The company operates in a single operating and reportable segment, private aviation services. It operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.